Search research articles
Contact Us
Filters
Showing results (91-100 of 123) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia
Richard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Lancet (London, England)
|
April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Harry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology
Peter L Greenberg, Maria R Baer, John M Bennett, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML
Vivian M Liu, Megan Othus, Jasmine Naru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Nitin Jain, Emily Curran, Neil M Iyengar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Myeloid growth factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncology
Jeffrey Crawford, Betsy Althaus, James Armitage, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 123) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia
Richard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Lancet (London, England)
|
April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Harry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology
Peter L Greenberg, Maria R Baer, John M Bennett, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML
Vivian M Liu, Megan Othus, Jasmine Naru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Nitin Jain, Emily Curran, Neil M Iyengar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Myeloid growth factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncology
Jeffrey Crawford, Betsy Althaus, James Armitage, et al.
Page
of 13